Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FURESTEM-RA + DMARDs
- Development stage
- Unknown
- Lead developer
- Kangstem Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
FURESTEM-RA + DMARDs is a combination therapy developed by Kangstem Biotech for the treatment of moderate to severe rheumatoid arthritis. The primary component, FURESTEM-RA (also known as K0101), consists of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) produced using the company's proprietary SELAF platform technology, which enables the production of high-purity, freeze-dried stem cells. These mesenchymal stem cells exert therapeutic effects through potent immunosuppressive and anti-inflammatory mechanisms, including the modulation of T-cell and B-cell activity and the secretion of various paracrine factors. In this therapeutic regimen, FURESTEM-RA is administered in combination with conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine. The therapy is currently in Phase 2b clinical trials, specifically targeting patients who have had an inadequate response to one or more standard anti-rheumatic treatments.
- Other names
- hUCB-MSCsallogeneic human umbilical cord blood-derived mesenchymal stem cells
Beyond the preview
Go deeper on FURESTEM-RA + DMARDs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FURESTEM-RA + DMARDs.